Warming a deep tumor to 41°C to make radiation and chemo hit harder
Regional deep hyperthermia is delivered by an external ring or array of RF electrode applicators — typically 8 to 24 dipole antennas — arranged circumferentially around the pelvis, abdomen, or limb containing a deep-seated tumor. Unlike thermal ablation, which uses a single needle electrode to destroy tissue at the probe tip, regional hyperthermia never touches the tumor: every applicator sits outside the body and couples energy in through the skin, converging it deep inside by geometry and phase, not by insertion.
Hyperthermia in oncology spans a wide temperature range with very different biology at each end. Regional (deep) hyperthermia deliberately targets a mild, sustainable elevation of 40–43°C inside the tumor — a range chosen because it changes tumor physiology and radiosensitivity without directly cooking tissue.
This is fundamentally different from thermal ablation techniques (radiofrequency ablation, microwave ablation, HIFU, cryoablation) that drive focal temperatures above 50–60°C to coagulate and kill tissue outright, usually via a percutaneous needle placed directly in the tumor. Regional hyperthermia applicators never enter the body — they are external antennas that project energy inward, and the target is a survivable, sensitizing temperature rather than a lethal one.
The distinction matters clinically: hyperthermia is almost never used alone. It is scheduled as an adjunct within 30–60 minutes of a radiotherapy fraction or a chemotherapy infusion, because its principal value is making those primary treatments more effective, not destroying tissue by heat itself.
Mild hyperthermia (40–43°C) and thermal ablation (>50°C) are governed by different biology entirely — coagulative necrosis versus reversible physiological sensitization — even though both start from the same idea: heat the tumor from outside the body.
A deep regional hyperthermia system such as the BSD-2000/Sigma-Eye arranges a ring of dipole antenna pairs (commonly 8–24 elements, grouped in rings of 4 or more) around the treated body region — pelvis for cervical, rectal, and bladder cancers; abdomen for sarcomas; limb for extremity sarcomas.
Each antenna does not touch the skin directly. Instead, a flexible water bolus — a bag of temperature-controlled, circulating deionized water — sits between the applicator and the body surface. This bolus does two jobs simultaneously:
• Impedance matching: water has a dielectric constant much closer to tissue than air, so RF energy couples into the body efficiently instead of reflecting at the skin • Surface cooling: circulating water near 10–20°C actively cools the skin and subcutaneous fat, which would otherwise absorb the most energy (being closest to every antenna) and overheat before the deep tumor ever reaches target temperature
Patient positioning and applicator geometry are planned from CT/MRI so the tumor sits as close as possible to the geometric center of the ring, where constructive interference from every channel overlaps most efficiently.
Every applicator in the ring transmits continuously — none of them alone could reach a deep tumor without also cooking the skin beneath it. What makes deep focusing possible is phased-array physics: each channel's phase and amplitude is tuned electronically so the individual RF waves overlap constructively at the tumor and destructively almost everywhere else, the same principle used in radar and ultrasound beamforming.
A single RF antenna radiating into tissue deposits most of its energy near the skin surface, where the wave is strongest, and loses intensity with depth. Placing many antennas around the body changes this entirely: at any point where several wavefronts arrive in phase, their amplitudes add; where they arrive out of phase, they cancel.
By electronically adjusting the phase (time delay) and amplitude of each of the 8–24 channels, the treatment planning system computes a phase pattern that makes every wavefront arrive in phase specifically at the tumor coordinates — and largely out of phase everywhere else, including the skin under any single antenna. The result is a specific absorption rate (SAR) hot spot deep inside the body without needing a hot spot at any individual applicator.
This is mathematically the same operation as electronic beam steering in radar phased arrays or transmit focusing in ultrasound: no antenna physically moves, but the effective focus can be steered in three dimensions purely by recalculating phase delays, guided by a patient-specific electromagnetic simulation built from the planning CT.
Deep regional systems typically operate in the 70–100 MHz band (some at lower frequencies still), which is a deliberate compromise:
• Lower RF frequencies (tens of MHz) penetrate deeper into tissue with less attenuation — necessary to reach centrally located pelvic or abdominal tumors • Higher frequencies would attenuate faster, concentrating too much energy near the surface, but they also allow tighter focal spots • At ~70–100 MHz the wavelength in tissue is roughly 30–40 cm, which sets the physical scale of the achievable focus — regional hyperthermia produces a broad heated volume around the tumor (several centimeters), not a millimeter-precision hot spot
This is why regional hyperthermia is described as targeting a "focal region" rather than a point, and why applicator ring diameter, patient body habitus, and tumor location all feed into the electromagnetic treatment plan before every session.
Phased-array RF focusing lets a system built entirely of external antennas reach a target 10–15 cm deep in the pelvis — the same electronic-steering principle that lets a radar dish-free phased array point a beam without physically moving anything.
Once RF energy is concentrated at the tumor by phase interference, it still has to become heat. That conversion happens through dielectric and resistive losses in tissue — the same physical mechanism that warms food in a microwave, applied here at RF rather than microwave frequencies and tuned to raise deep tissue by only a few degrees rather than boil it.
The oscillating RF electric field drives ions and polar molecules (mostly water) in tissue to constantly reorient and migrate, and that molecular friction dissipates energy as heat. The rate of energy deposition per unit mass is the Specific Absorption Rate (SAR), measured in W/kg:
SAR = σ·E² / (2ρ)
where σ is tissue electrical conductivity, E is the local electric field magnitude created by the phased array, and ρ is tissue density. SAR is not temperature — it is the power being deposited; temperature rise depends on SAR, tissue heat capacity, exposure duration, and how fast blood flow removes heat.
In the bioheat framework, local temperature rise over time follows approximately:
ΔT/Δt ∝ SAR/c − (perfusion-driven cooling term)
Early in a session (this stage), perfusion has not yet ramped up much, so absorbed SAR translates fairly directly into a steadily climbing focal temperature — typically reaching the low end of the therapeutic 40–43°C window within 20–30 minutes for a well-focused, well-planned treatment.
The 40–43°C window is not an arbitrary regulatory limit — it reflects where the desired biology (sensitization, reversible physiological stress) operates without crossing into direct cytotoxicity or coagulation:
• Below ~40°C: minimal biological effect: not enough thermal stress to meaningfully change perfusion, oxygenation, or drug uptake • 40–43°C (the therapeutic window): reversible protein and membrane stress, measurable increase in blood flow and oxygen delivery, sensitization of DNA repair pathways — the sweet spot exploited by regional hyperthermia • 43–45°C: thermal damage becomes increasingly likely with prolonged exposure — treatment protocols keep cumulative thermal dose (CEM43, cumulative equivalent minutes at 43°C) within safety limits • Above ~50°C: coagulative necrosis — the ablation regime, achieved deliberately by RFA/microwave/HIFU probes, not by regional hyperthermia applicators
Staying inside the mild-hyperthermia band while still reaching a therapeutically meaningful temperature at a deep, moving, perfused target is precisely why continuous multi-channel feedback control (next stage) is required rather than simply running every antenna at fixed power.
Mild hyperthermia's therapeutic window is narrow by design: 40°C is often too cool to sensitize meaningfully, while sustained exposure above ~45°C shifts the biology from reversible sensitization toward outright thermal injury — which is a different treatment (ablation), not a stronger version of this one.
As tumor and surrounding tissue warm, the body responds exactly as it would to any local heat stress: blood vessels dilate and local perfusion rises sharply, carrying heat away just as effectively as it would carry away metabolic heat from exercising muscle. This physiological cooling response is powerful enough that, left uncorrected, it can stall temperature rise entirely — which is why regional hyperthermia is a closed-loop, continuously adjusted therapy rather than a fixed-power exposure.
Blood entering a heated region at core body temperature (~37°C) acts as a coolant: it absorbs heat from the warmed tissue and carries it away to be redistributed throughout the body. As local temperature rises into the 40–43°C range, vasodilation increases regional blood flow by roughly 2–4× baseline, and this perfusion-driven cooling grows stronger the hotter the tissue gets — a built-in negative feedback loop.
The practical consequence: the same RF power that raised temperature quickly during initial heating (Stage 3) becomes progressively less effective at the same setting as perfusion ramps up. Without compensation, temperature would plateau below target or oscillate unpredictably as perfusion and heating fight each other.
Tumor vasculature complicates this further: tumor blood vessels are often chaotic, leaky, and poorly regulated compared to normal tissue, so the cooling response can be spatially uneven — parts of a tumor may heat differently from adjacent normal tissue or from each other, which is part of why deep hyperthermia requires patient-specific electromagnetic and thermal modeling rather than a one-size-fits-all power setting.
To hold a stable target temperature despite rising perfusion, the treatment system continuously measures temperature — via invasive catheter-based thermal probes placed in or near the tumor, non-invasive MR thermometry in MR-guided systems, or model-based estimation — and feeds that measurement back into the phased-array controller.
Each of the independently phased RF channels can have its amplitude (and to a lesser extent phase) adjusted many times per minute, so the system is constantly trading power up or down across the whole array to counteract local cooling and hold the focal region inside the 40–43°C band without exceeding safety limits, particularly at the skin and normal tissue closest to each applicator.
Thermal dose is tracked cumulatively using CEM43 (cumulative equivalent minutes at 43°C), a standardized metric that converts any time-temperature history into an equivalent exposure at the 43°C reference point, allowing clinicians to compare thermal dose across patients and sessions and to keep cumulative exposure within a safe, defined range even as instantaneous power fluctuates to counter blood-flow cooling.
The single hardest engineering problem in regional hyperthermia is not reaching 41°C — it is holding it there. Rising local blood flow actively works against the treatment, so power must be continuously re-optimized across every channel throughout the session.
Mild hyperthermia at 40–43°C is, on its own, rarely enough to kill a solid tumor. Its clinical value comes from what it does to the tumor's biology in the hours around a radiotherapy fraction or chemotherapy infusion: better oxygen delivery, greater drug penetration, and direct interference with the tumor cell's ability to repair the DNA damage those treatments cause. Combined, these effects have produced some of the most consistent, positive randomized trial results in the hyperthermia literature.
Solid tumors routinely outgrow their blood supply, leaving core regions chronically hypoxic. Hypoxic cells are two to three times more resistant to radiotherapy than well-oxygenated cells, because radiation-induced DNA damage relies partly on oxygen to become chemically fixed and lethal (the oxygen enhancement ratio) — hypoxic tumor cores are one of the best-established reasons radiotherapy under-performs in bulky, poorly vascularized tumors.
Mild hyperthermia directly counters this: the vasodilation and perfusion increase described in Stage 4 does not stop at cooling the treated volume — it also increases oxygen delivery into previously hypoxic tumor regions. Better-oxygenated tumor cells become substantially more sensitive to radiation-induced DNA damage, which is the principal mechanistic reason hyperthermia timed closely around radiotherapy improves outcomes rather than simply adding independent tumor kill.
Heat also directly impairs DNA damage-repair pathways — particularly homologous recombination repair, partly through thermal effects on the repair protein BRCA2 — meaning the same amount of radiation-induced DNA damage is more likely to remain unrepaired and lethal to the tumor cell.
With chemotherapy, mild hyperthermia acts through complementary mechanisms:
• Increased tumor blood flow and vascular permeability improve drug delivery into a tumor that is often poorly perfused at baseline • Heat increases the rate of several chemotherapy drug-DNA and drug-membrane interactions, effectively increasing potency at the same systemic dose (true synergy for agents such as cisplatin and some alkylating agents) • Heat-triggered liposomal drug carriers (e.g., thermosensitive liposomal doxorubicin) are designed to release their payload specifically inside the 40–43°C heated volume, concentrating drug release at the tumor while sparing normal tissue
Because the sensitizing effect is time-limited, hyperthermia sessions are scheduled deliberately close to (typically within about an hour of) the radiotherapy fraction or chemotherapy infusion — the biology being exploited fades once tissue cools back to baseline temperature.
Regional hyperthermia has one of the more mature randomized-trial evidence bases in thermal therapy. The landmark Dutch Deep Hyperthermia Trial (van der Zee et al., Lancet 2000) randomized patients with locally advanced pelvic tumors (cervix, rectum, bladder) to radiotherapy alone versus radiotherapy plus regional hyperthermia, and found substantially improved complete response and 3-year local control with hyperthermia added — for cervical cancer, complete response rose from roughly 57% to 83%.
Subsequent meta-analyses (e.g., Datta et al.) pooling multiple cervical cancer trials reported complete response rates improving from roughly 40% with radiotherapy alone to roughly 68% with hyperthermia added, alongside improved overall survival in several trial populations. Positive randomized results have also been reported in locally advanced rectal cancer, muscle-invasive bladder cancer, soft-tissue sarcoma (pre-operative chemotherapy + hyperthermia), and recurrent breast cancer on the chest wall.
Based on this evidence, deep regional hyperthermia delivered by systems such as the BSD-2000/Sigma-Eye is incorporated into treatment guidelines in several countries as an adjunct to radiotherapy or chemoradiotherapy for selected pelvic and soft-tissue malignancies, typically at specialized centers with the equipment and thermal-dosimetry expertise required to plan and monitor treatment safely.
In the Dutch Deep Hyperthermia Trial, adding regional hyperthermia to radiotherapy nearly matched what an entirely separate systemic treatment might achieve — evidence that a few degrees of well-targeted, well-controlled heat can meaningfully change how a tumor responds to a therapy it was already receiving.